Breathlessness is a common and disabling symptom in patients with chronic obstructive pulmonary disease (COPD) ([@bib1]) and is defined as "a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity" as interpreted by the individual ([@bib2]). Progression of COPD is associated with worsening breathlessness accompanied by a downward spiral of symptom-induced inactivity ([@bib3]), muscle deconditioning and weakness ([@bib4]), and significant negative impact on health-related quality of life and survival ([@bib5]--[@bib8]).

The emphysema-hyperinflated phenotype is characterized by a heightened sense of dyspnea and exercise intolerance caused by mechanical constraints imposed on ventilation at rest and during activity ([@bib9]). The physiological model of patient-reported shortness of breath in COPD presented by Jolley and Moxham ([@bib10]) describes the effects of daily activities on increasing respiratory muscle load-capacity imbalance, neural respiratory drive, and neuromechanical dissociation, which are magnified in severe emphysema and hyperinflation. Hyperinflation is a key contributor to an individual's perception of breathlessness and to exercise limitation ([@bib11], [@bib12]), and is a predictor not only of risk of exacerbation ([@bib13]) but of all-cause mortality ([@bib14], [@bib15]), prompting targeted strategies to reduce hyperinflation.

In selected individuals, lung volume reduction surgery has been shown to improve lung function, exercise capacity, dyspnea, and quality of life, and to extend survival ([@bib16], [@bib17]). However, only a small number of patients with COPD are eligible for lung volume reduction surgery, periprocedural morbidity and mortality is relatively high, and only a few hundred procedures are performed annually in the United States. Recent efforts have been focused on the development of less invasive approaches. Bronchoscopic lung volume reduction using the Zephyr Endobronchial Valve (Zephyr Valve; Pulmonx Corporation) has been shown in multiple randomized controlled trials (RCTs) to reduce hyperinflation and to improve lung function, exercise tolerance, dyspnea, and overall quality of life in individuals with heterogeneous ([@bib18]--[@bib21]) or homogeneous ([@bib22]) emphysema and little to no interlobar collateral ventilation.

COPD is a multifaceted condition and assessment of airflow limitation alone does not adequately reflect the burden of the disease. FEV~1~ has been shown to correlate poorly with patient-reported outcomes (PROs), including dyspnea, activity, and health status ([@bib23], [@bib24]). Furthermore, there is a significant disparity between subjects\' perception of disease severity and the degree of severity indicated by a unidimensional breathlessness scale ([@bib25]), which may lead to undertreatment. Therefore, to quantify symptoms, the most efficient and objective way is to assess symptom severity, activity limitation, and psychosocial status using multidimensional patient-centric measures ([@bib26]). In doing so, a better estimate of treatment effects may be gained.

The LIBERATE (Lung Function Improvement after Bronchoscopic Lung Volume Reduction with Pulmonx Endobronchial Valves used in Treatment of Emphysema) study is the largest multicenter prospective RCT of the Zephyr Valve in patients with severe heterogeneous emphysema, hyperinflation, and little to no interlobar collateral ventilation assessed using the Chartis System (Pulmonx Corp.). Multiple patient-centric assessments were included in the study to allow an in-depth evaluation of the impact of reduced hyperinflation on dyspnea and symptoms that are most meaningful to patients with COPD. Published PROs have so far focused on the modified Medical Research Council (mMRC) Dyspnea Scale and the St. George's Respiratory Questionnaire (SGRQ) total score. The importance of PROs in a comprehensive evaluation of response to treatment is recognized and recommended in recent guideline updates ([@bib27]).

We present the PROs of multidimensional measures of *1*) dyspnea, from the Transitional Dyspnea Index (TDI), focal score; the COPD Assessment Test (CAT; breathlessness on hill/stairs); Borg; and the EXAcerbations of Chronic Pulmonary Disease Tool \[EXACT\]--PRO, dyspnea domain; *2*) activity, from the TDI, magnitude of task/effort/functional impairment; CAT (limited activities); and the SGRQ, activity domain; and *3*) psychosocial status, from the SGRQ, impacts domain, and CAT (confidence and energy) at 12 months after their bronchoscopic lung volume reductions with Zephyr Valves beyond the mMRC Dyspnea Scale and the SGRQ, total score, that were previously reported in the LIBERATE trial ([@bib21]). Evaluation of these symptom metrics in this study population before and after endobronchial valve implantation has not been published.

Some of the results have previously been reported in abstract form ([@bib28]).

Methods
=======

The LIBERATE study design (NCT 01796392) has been published previously ([@bib21]). The multicenter study conducted under a U.S. Food and Drug Administration--approved Investigational Device Exemption for the Zephyr Valve was approved by the respective institutional review boards or ethics committees at each site, and all participating subjects were provided written informed consent. The study protocol is summarized in the online supplement.

Multiple discrete and validated self-administered questionnaires were completed at baseline and follow-up visits, and have not been previously reported (*see* Table E1 in the online supplement for timing of each assessment). These included: for dyspnea, the TDI, focal score; Borg scale of perceived exertion; EXACT-PRO diary, dyspnea domain; and the CAT question regarding breathlessness on hill/stairs; for activity, the TDI, magnitude of task, magnitude of effort, and functional impairment; the CAT questions regarding limited activities; and the SGRQ, activity domain; and, for psychosocial status, the SGRQ, impacts domain, and the CAT questions regarding confidence and energy. Neither the study participants nor the assessing physicians were blinded to the randomization. At follow-up assessments, study participants were not reminded of, and thus were not aware of, their baseline scores.

Study participants also maintained a daily diary in which they noted adherence with the pulmonary rehabilitation program, completed the EXACT-PRO questionnaire, and noted health status changes. The following question was administered as part of the daily diary: "Mark the scale to show the intensity of the emphysema symptoms you had today (scale of 0 = none to 10 = intolerable)." Although this question was not validated, it asks a global question of clinical interest using a visual analogue scale of 0 to 10 for rating the subject's perception of emphysema symptom intensity every day. Days that were better or worse were determined by a follow-up score that was above (worse) or below (better) the baseline score.

Statistical Analysis
--------------------

All data were collected prospectively; however, inferential statistics for the SGRQ domains, the TDI domains, the mMRC Dyspnea Scale, CAT individual questions, Borg, and EXACT-PROs were not prospectively specified in the study protocol and hence are considered *post hoc*. Statistical analyses were performed using SAS version 9.3 (SAS Institute). Descriptive statistics include means, standard deviations, and 95% confidence intervals. Change from baseline to 12 months and the percentage of subjects meeting a minimal clinically important difference (MCID; or "responder") per group were reported using an MCID of greater than or equal to 15% increase for FEV~1~ ([@bib29]), greater than or equal to 25 m increase for 6-minute-walk distance (6MWD) ([@bib30]), greater than or equal to a 4-point reduction for the SGRQ ([@bib31]), greater than or equal to a 1-point increase for the TDI ([@bib32]), and greater than or equal to a 1-point reduction for mMRC Dyspnea Scale ([@bib33]) and Borg ([@bib34]). Changes from baseline were reported for EXACT-PRO, dyspnea domain, and individual CAT ([@bib35]) questions only.

Missing data for the prospectively defined primary and secondary endpoints were imputed as baseline carried forward for deaths, by linear interpolation for intermittent missing values, by multiple imputation methods for truncated missing values. Cohen's effect size was calculated as the difference in means divided by pooled standard deviation (referred to as Cohen's D). Continuous variables were compared with the Wilcoxon rank sum (for nonparametric data) or an analysis of covariance with the respective baseline value as the covariate (for parametric data), and categorical variables were compared with the Fisher exact test.

Scatter plots and Pearson correlation coefficients were performed to assess the relationships between hyperinflation (residual volume \[RV\] and RV/TLC) and dyspnea (EXACT-PRO), lung function (FEV~1~), quality of life (the SGRQ, total score), and exercise capacity (6MWD). Statistical significance was determined at the *P* \< 0.05 level. Poisson regression adjusted for each subject's length of follow-up was used to analyze daily diary data for days that were better or worse from baseline.

Results
=======

Subject Characteristics
-----------------------

A total of 190 patients with severe heterogeneous emphysema and hyperinflation with little or no collateral ventilation in the target lobe were enrolled with a 2 to 1 randomization (128 Zephyr Valve and 62 standard of care \[SoC\]). Baseline demographic and clinical characteristics data have previously been reported ([@bib21]) and are provided for reference in Table E2. Except for a higher proportion of Global Initiative for Chronic Obstructive Lung Disease stage IV subjects in the SoC group, there were no differences between groups for the other variables. Twelve subjects did not complete the 12-month assessments: 9 in the Zephyr Valve group (2 withdrew consent, 2 withdrawn by investigators, and 5 died) and 3 in the SoC group (2 withdrawn by investigators and 1 died) ([@bib21]).

Dyspnea Measures
----------------

Multiple measures of dyspnea showed statistically significant improvements in the Zephyr Valve group compared with SoC at 12 months ([Table 1](#tbl1){ref-type="table"}). The mean group differences for the change from baseline to 12 months (Δ Zephyr Valve--SoC) were −0.8 points for mMRC Dyspnea Scale (*P* \< 0.001; previously reported \[[@bib21]\]); 4.3 points for the TDI, focal score (*P* \< 0.001); −0.9 points for Borg after the 6-minute-walk test (*P* \< 0.001); −8.8 points for the EXACT-PRO, dyspnea domain (*P* = 0.002); and −0.6 points for the CAT, dyspnea question (*P* = 0.002).

###### 

Dyspnea, activity, and psychosocial status outcomes: absolute change from baseline at 12 months

                                                                                                    Zephyr Valve (*n* = *128*)   SoC (*n* = *62*)    ∆Zephyr-SoC     Effect Size      *P* Value                                                                       
  ------------------------------------------------------------------------------------------------ ---------------------------- ------------------ --------------- --------------- --------------- ---------------- ------------------------------------------ ------ --------------------------------------------
  Dyspnea outcomes                                                                                                                                                                                                                                                    
   mMRC Dyspnea Scale[\*](#tblfn1){ref-type="table-fn"}, points                                             2.4 ± 0.97              1.9 ± 1.04       −0.5 ± 1.17     2.2 ± 0.83      2.5 ± 0.95       0.3 ± 1.03     −0.8[^†^](#tblfn2){ref-type="table-fn"}    0.73   \<0.001[^‡^](#tblfn3){ref-type="table-fn"}
   TDI[\*](#tblfn1){ref-type="table-fn"}[^§^](#tblfn4){ref-type="table-fn"}, focal score, points               ---                     ---           2.3 ± 5.25          ---             ---         −2.0 ± 4.35      4.3[^†^](#tblfn2){ref-type="table-fn"}    0.89   \<0.001[^‖^](#tblfn5){ref-type="table-fn"}
   Borg after 6MWT[^¶^](#tblfn6){ref-type="table-fn"}, points)                                             4.45 ± 2.17             3.93 ± 2.18      −0.45 ± 2.24     4.94 ± 2.28     5.36 ± 2.23     0.42 ± 2.37     −0.87[^†^](#tblfn2){ref-type="table-fn"}   0.38   \<0.001[^‡^](#tblfn3){ref-type="table-fn"}
   EXACT-PRO, dyspnea domain, points                                                                       49.2 ± 13.32            43.5 ± 17.59      −5.5 ± 18.6    48.1 ± 10.83    51.1 ± 14.66     3.3 ± 11.25     −8.8[^†^](#tblfn2){ref-type="table-fn"}    0.57    0.002[^‡^](#tblfn3){ref-type="table-fn"}
   CAT Q4[\*\*](#tblfn7){ref-type="table-fn"}, breathlessness, points                                       4.1 ± 1.11              3.5 ± 1.39       −0.5 ± 1.56     4.1 ± 1.00      4.2 ± 1.03       0.1 ± 1.20     −0.6[^†^](#tblfn2){ref-type="table-fn"}    0.43    0.002[^‡^](#tblfn3){ref-type="table-fn"}
  Activity outcomes                                                                                                                                                                                                                                                   
   6MWD[\*](#tblfn1){ref-type="table-fn"}, m                                                               311.3 ± 81.3           323.9 ± 111.9     12.98 ± 81.54   301.9 ± 78.5    276.3 ± 93.5    −26.33 ± 81.50   39.3[^†^](#tblfn2){ref-type="table-fn"}    0.48    0.002[^‡^](#tblfn3){ref-type="table-fn"}
   TDI[^§^](#tblfn4){ref-type="table-fn"}, magnitude of task, points                                           ---                     ---            0.8 ± 1.8          ---             ---          −0.6 ± 1.5      1.4[^†^](#tblfn2){ref-type="table-fn"}    0.85   \<0.001[^‖^](#tblfn5){ref-type="table-fn"}
   TDI[^§^](#tblfn4){ref-type="table-fn"}, magnitude of effort, points                                         ---                     ---            0.8 ± 1.9          ---             ---          −0.7 ± 1.5      1.5[^†^](#tblfn2){ref-type="table-fn"}    0.86   \<0.001[^‖^](#tblfn5){ref-type="table-fn"}
   TDI[^§^](#tblfn4){ref-type="table-fn"}, functional impairment, points                                       ---                     ---            0.7 ± 1.8          ---             ---          −0.7 ± 1.6      1.4[^†^](#tblfn2){ref-type="table-fn"}    0.82   \<0.001[^‖^](#tblfn5){ref-type="table-fn"}
   CAT Q5[^††^](#tblfn8){ref-type="table-fn"}, activity, points                                             3.3 ± 1.21              2.6 ± 1.47       −0.7 ± 1.7      3.5 ± 1.05      3.5 ± 1.04       0.0 ± 1.3      −0.7[^†^](#tblfn2){ref-type="table-fn"}    0.46   \<0.001[^‡^](#tblfn3){ref-type="table-fn"}
   SGRQ, activity domain, points                                                                          78.80 ± 13.73           66.26 ± 22.28     −12.0 ± 21.46   78.35 ± 12.79   78.87 ± 14.31    0.70 ± 14.31    −12.7[^†^](#tblfn2){ref-type="table-fn"}   0.70   \<0.001[^‡^](#tblfn3){ref-type="table-fn"}
  Psychosocial status                                                                                                                                                                                                                                                 
   SGRQ, total[\*](#tblfn1){ref-type="table-fn"}, points                                                  55.15 ± 14.09           47.35 ± 18.39     −7.55 ± 15.71   53.10 ± 14.14   53.12 ± 15.41   −0.50 ± 15.50    −7.05[^†^](#tblfn2){ref-type="table-fn"}   0.45    0.004[^‡^](#tblfn3){ref-type="table-fn"}
   SGRQ, impacts domain, points                                                                           43.17 ± 17.79           33.17 ± 19.09     −9.58 ± 19.00   39.40 ± 18.09   38.92 ± 19.41    0.14 ± 17.34    −9.72[^†^](#tblfn2){ref-type="table-fn"}   0.53    0.004[^‡^](#tblfn3){ref-type="table-fn"}
   CAT Q6[^‡‡^](#tblfn9){ref-type="table-fn"}, confidence, points                                           2.0 ± 1.65              1.4 ± 1.49       −0.6 ± 1.78     1.8 ± 1.64      1.8 ± 1.60       0.1 ± 1.81     −0.7[^†^](#tblfn2){ref-type="table-fn"}    0.39    0.024[^‡^](#tblfn3){ref-type="table-fn"}
   CAT Q8[^§§^](#tblfn10){ref-type="table-fn"}, energy, points                                              3.0 ± 1.30              2.4 ± 1.36       −0.6 ± 1.57     2.9 ± 1.32      2.9 ± 1.38       0.1 ± 1.67     −0.7[^†^](#tblfn2){ref-type="table-fn"}    0.43    0.014[^‡^](#tblfn3){ref-type="table-fn"}

*Definition of abbreviations*: 6MWD = 6-minute-walk distance; 6MWT = 6-minute-walk test; CAT Q =  Chronic obstructive pulmonary disease Assessment Test question; EXACT-PRO = EXAcerbations of Chronic pulmonary disease Tool--Patient-Reported Outcome; mMRC = modified Medical Research Council; SGRQ = St. George's Respiratory Questionnaire; SoC = standard of care; TDI = Transitional Dyspnea Index.

Values are mean ± standard deviation.

Minimal clinically important difference: Borg score, −1 point; CAT, −2 points; mMRC, −1 point; SGRQ, −4 points; and the TDI, +1 point.

Previously reported ([@bib21]).

Favors the Zephyr Valve (intervention group).

*P* value from an analysis of covariance with factor of treatment groups and baseline value as covariate.

The TDI responses reflect participants' perception of change from baseline at the time of assessment (12 mo).

*P* value from the Wilcoxon rank sum test.

Borg scale measured after completing the 6MWT was used for comparison owing to very low baseline pretest scores creating a ceiling effect on the analysis of change.

CAT Q4: "When I walk up a hill or one flight of stairs, I am not breathless."

CAT Q5: "I am not limited doing any activities at home."

CAT Q6: "I am confident leaving my home despite my condition."

CAT Q8: "I have lots of energy."

The absolute changes from baseline to 12 months for the SGRQ domains, the TDI domains, and the individual questions in CAT are provided in Figures E1--E3.

Dyspnea Responders
------------------

As shown in [Figure 1](#fig1){ref-type="fig"}, significantly more responders at 12 months were observed for the Zephyr Valve compared with SoC group patients for improvements in mMRC Dyspnea Scale of greater than or equal to a 1-point decrease (48.2% vs. 19.0%, respectively; *P* \< 0.001) and for the TDI, focal score, of greater than or equal to a 1-point increase (61.9% vs. 15.8%, respectively; *P* \< 0.001). Responders for Borg dyspnea score after the 6-minute-walk test favored the Zephyr Valve over SoC, but this was not statistically significant (≥1-point decrease; 44.1% vs. 35.1%, respectively; *P* = 0.321).

![Responders based on minimal clinically important difference of greater than or equal to a 1-point decrease for the mMRC Dyspnea Scale and Borg after a 6MWT, and greater than or equal to a 1-point increase for the TDI, focal score, from baseline to 12 months. Dark blue bars represent the Zephyr Valve group and the light blue bars represent the SoC group. 6MWT = 6-minute-walk test; mMRC = modified Medical Research Council; SoC = standard of care; TDI = Transitional Dyspnea Index.](AnnalsATS.201909-666OC_f1){#fig1}

Activity Measures
-----------------

Multiple measures of activity levels assessed at 12 months showed statistically significant improvements in the Zephyr Valve group compared with SoC group (*see* [Table 1](#tbl1){ref-type="table"}). An improvement in the 6MWD of 39.3 m in favor of the Zephyr Valve group was reported previously ([@bib21]).

Activity Responders
-------------------

Significantly more responders at 12 months were observed for the Zephyr Valve group compared with SoC for 6MWD (previously reported \[[@bib21]\]; 41.8% vs. 19.6%, respectively; *P* = 0.003), the TDI, magnitude of task (60.5% vs. 13.8%, respectively; *P* \< 0.001); the TDI, magnitude of effort (58.3% vs. 15.5%, respectively; *P* \< 0.001); the TDI, functional impairment (57.9% vs. 15.5%, respectively; *P* \< 0.001); and the SGRQ, activity domain (57.4% vs. 27.1%, respectively; *P* \< 0.001) ([Figure 2](#fig2){ref-type="fig"}).

![Responders based on minimal clinically important difference of greater than or equal to a 25 m increase for 6MWD, greater than or equal to a 1-point increase for the TDI domain scores (magnitude of task, magnitude of effort, and functional impairment), and greater than or equal to a 4-point decrease for the SGRQ, activity domain. Dark blue bars represent the Zephyr Valve group and the light blue bars represent the SoC group. 6MWD = 6-minute-walk distance; SGRQ = St. George's Respiratory Questionnaire; SoC = standard of care; TDI = Transitional Dyspnea Index.](AnnalsATS.201909-666OC_f2){#fig2}

Psychosocial Status
-------------------

At 12 months, statistically significant improvements for the Zephyr Valve group over SoC group were demonstrated for absolute changes from baseline to 12 months for the SGRQ, total score (−7.1 points; *P* = 0.004; previously reported \[[@bib21]); the SGRQ, impact score (−9.7 points; *P* = 0.004); and CAT questions regarding confidence (−0.7 points; *P* = 0.024) and energy (−0.7 points; *P* = 0.014) (*see* [Table 1](#tbl1){ref-type="table"}).

There were significantly more SGRQ responders at 12 months in the Zephyr Valve group compared with SoC, with 56.2% versus 30.2%, respectively, using an MCID of −4 points (previously reported in Reference [@bib21]). For the SGRQ, impacts domain, the responder rates were 63.2% versus 42.4% (Zephyr Valve vs. SoC, respectively; *P* = 0.01) using an MCID of −4 points.

Daily Diary Scores
------------------

Compared with SoC, the Zephyr Valve group had significantly more days per year when their emphysema symptom intensity was better than baseline (≥1-point improvement) with 206 versus 102 days (Zephyr Valve vs. SoC, respectively; *P* \< 0.001; Poisson regression adjusted for each subject's length of follow-up) and significantly fewer days that were worse than baseline (≥1-point worsening) with 95 versus 122 days (Zephyr Valve vs. SoC, respectively; *P* \< 0.001). Patients in the Zephyr Valve group experienced the same degree of emphysema symptom intensity as at baseline on fewer days compared with the SoC patients (64 days vs. 141 days, Zephyr Valve vs. SoC, respectively; *P* \< 0.001). The weekly averages of the daily change from baseline in the emphysema symptom intensity over the 12 months is shown in [Figure 3](#fig3){ref-type="fig"}.

![Emphysema symptom intensity presented as weekly averages of the daily change from baseline values up to 12 months for the Zephyr Valve (blue closed squares) versus SoC (blue open squares) groups. SoC = standard of care.](AnnalsATS.201909-666OC_f3){#fig3}

As shown in [Table 1](#tbl1){ref-type="table"}, the calculated effect size for all parameters assessed ranged from 0.38 to 0.89 and in all cases were greater than the Cohen's D of 0.2, which represents a small effect size.

Relationships between Reduction in Hyperinflation and Effectiveness Assessed Using PRO Measures
-----------------------------------------------------------------------------------------------

Clinically meaningful improvement in static hyperinflation at 12 months favoring the Zephyr Valve group has been reported ([@bib21]). [Figure 4](#fig4){ref-type="fig"} shows that reductions in RV (L) and RV/TLC are significantly correlated with improvements in FEV~1~; 6MWD; the SGRQ, total score; and dyspnea (EXACT-PRO).

![Correlation between reduction in hyperinflation (RV) and RV/TLC ratio, and changes from baseline to 12 months, for postbronchodilator FEV~1~; 6MWD; the SGRQ; and EXACT-PRO, dyspnea domain. Data are for the Zephyr Valve group. 6MWD = 6-minute-walk distance; BD = bronchodilator; EBV = Zephyr endobronchial valve; EXACT-PRO = EXAcerbations of Chronic pulmonary disease Tool--Patient-Reported Outcome; FEV~1~ = forced expiratory volume in 1 second; RV = residual volume; SGRQ = St. George's Respiratory Questionnaire; TLC = total lung capacity.](AnnalsATS.201909-666OC_f4){#fig4}

Discussion
==========

This *post hoc* analysis of data from the LIBERATE multicenter RCT demonstrated statistically significant and clinically meaningful improvements in multiple patient-reported measures of dyspnea, activity, and psychosocial status favoring the Zephyr Valve over SoC at 12 months. The findings of this study expand on the results of RCTs evaluating the Zephyr Valve that have previously demonstrated physiological benefits and improvements in several measures of health-related quality of life, principally using the mMRC Dyspnea Scale and the SGRQ ([@bib18]--[@bib22], [@bib36]). It is also consistent with a meta-analysis that demonstrated a correlation between lung volume reduction and clinical benefit ([@bib37]). Of particular significance is the finding that the effect size based on Cohen's D is moderate to large for each of the parameter assessed.

Dyspnea is usually the most burdensome symptom in patients with COPD and is frequently multifactorial in origin ([@bib38]). Hyperinflation is a key factor driving exertional dyspnea in an individual with advanced emphysema ([@bib11]). Multiple PROs demonstrated statistically significant improvements in the Zephyr Valve group compared with SoC at 12 months, notably the TDI, focal score, and the EXACT-PRO, dyspnea domain. The TDI demonstrates a high correlation between dyspnea and stage of disease severity ([@bib39]), and measures aspects of daily living as they relate to the amount of breathlessness experienced ([@bib40]). The EXACT-PRO offers a validated daily diary--based symptom assessment that helps to better characterize exacerbations ([@bib41]) and reduce the recall bias affecting 60% of events that go unreported ([@bib42]). Use of these questionnaires complement the information obtained from lung function measurements, helping to provide a more consistent description of an individual's sensation of breathlessness in response to lung volume reduction treatment.

Most patients with COPD are relatively inactive, spending significantly less time standing and walking than persons without COPD ([@bib43]). Dyspnea is the principal symptom limiting exercise in patients with advanced COPD, leading to activity avoidance ([@bib3], [@bib43]--[@bib45]). It is important to break this cycle because reduced physical activity is a predictor of future risk of exacerbation, hospitalization, and early mortality ([@bib46], [@bib47]). Multiple measures of activity levels in patients treated with Zephyr Valves showed statistically significant improvements compared with SoC at 12 months, notably the TDI measures of effort, task, and functional impairment. These changes in activity levels can be very meaningful for patients. For example, a 3-point change in the TDI, focal score, implies a return to most work/leisure activities previously impacted, and 54.9% of patients treated with Zephyr Valve achieved this in LIBERATE.

The impact of COPD is not limited to the physical restrictions levied on the lifestyle of the patient. The experience of breathlessness "derives from interactions among multiple physiological psychological, social, and environmental factors, and may induce secondary physiological and behavioural responses" ([@bib2]). Breathlessness is associated with panic, anxiety, and depression ([@bib48]). The inability to engage in activities of daily living can be one of the most distressing symptoms for patients with COPD. The opportunity to improve quality of life and permit resumption, even in part, of familiar activities is highly desirable ([@bib49]). Our findings show that patients using the Zephyr Valve had improvements in psychosocial status, demonstrated by statistically significant improvements for patients using the Zephyr Valve over SoC in the SGRQ, impacts domain, and in CAT questions on patient confidence and energy.

Patients frequently report good and bad days with significant fluctuations over time ([@bib50]--[@bib53]). The quantitative improvement in all three aspects of breathlessness, activity levels, and psychosocial well-being measured at specified time points is also reflected in the daily diary assessment of patients, with those using the Zephyr Valve experiencing significantly more days that were better and fewer days that were worse over 12 months.

The improvements in multidimensional PROs were correlated with reduction in hyperinflation and elaborate on the clinical benefits observed in individuals undergoing this treatment ([@bib37]). Utilization of varied multidimensional questionnaires and of a daily diary assessment tool, as demonstrated in this study, afford a more comprehensive evaluation of the impact of the Zephyr Valve that is personalized to the symptoms of the individual and supports a phenotype-based management strategy as advocated by the Global Initiative for Chronic Obstructive Lung Disease guidelines ([@bib38]). These data add to the growing evidence base for the Zephyr Valve accomplishing and maintaining improvements that are not limited to lung function and objective exercise assessment but, importantly, to disease-specific symptoms and health-related quality of life, which permits patients the ability to reengage in their activities of daily living.

The strengths of the study include the use of standardized, validated, disease-specific, treatment-responsive instruments such as the SGRQ, CAT, and the TDI that provide a complement and refinement to previously published physiological data that is meaningful to the individual, and which is crucial to guide therapeutic management. Moreover, a daily diary assessment adds greater detail and context to what is a variable tapestry of symptoms from day to day. Furthermore, they provide an easy and cost-efficient way for acquiring data to characterize complex issues such as breathlessness and health-related quality of life in COPD that cannot be achieved by any one physiological correlate ([@bib26]). Lastly, the presence of a SoC group out to 12 months affords more accurate measurement of the impact of the Zephyr Valve on these multidimensional metrics. Limitations of the study include the use of these qualitative tools that can be subject to recall bias ([@bib54]) and could be further confounded due to the lack of blinding. Neither the study participants nor the assessing physicians were blinded to the randomization, which could introduce bias for self-reported outcomes. However, the strong correlation between reduction in hyperinflation as assessed by a reduction in RV and RV/TLC ratio, both of which are objective measures, and the changes from baseline to 12 months for postbronchodilator FEV~1~; 6MWD; the SGRQ score; and the EXACT-PRO, dyspnea domain, suggest that the results are robust. It should also be noted that the number of patients who did not complete the 12-month assessments was greater in those randomized to Zephyr Valves than in the SoC group, which could have biased the results toward benefit. Finally, a select group of patients with severe emphysema and hyperinflation with little or no collateral ventilation was treated, and the results cannot be generalized to other grades of airflow limitation.

Conclusions
-----------

*Post hoc* analysis of data from the LIBERATE study demonstrate that patients with severe emphysema and hyperinflation who achieve lung volume reductions following treatment with Zephyr Valves experience moderate to large improvements in multidimensional scores for breathlessness, activity, and psychosocial parameters that may permit reengagement in activities of daily living out to at least 12 months. The interruption of the downward spiral of symptom-induced inactivity, muscle deconditioning, and ensuing weakness allows patients to experience improved activity, feeling of well-being, more confidence, and a better quality of life. These results supplement the findings of published randomized controlled studies in patients with heterogeneous ([@bib18]--[@bib21]) and those with homogeneous ([@bib22]) emphysema, in whom accompanying improvements in lung function, exercise capacity, dyspnea, and overall quality of life have consistently been shown.
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